Navigation Links
The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million
Date:7/22/2014

BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for interventional cardiology (IC) devices in Canada will remain relatively stagnant at a value of around $80 million through 2022. This is despite the fact that percutaneous coronary intervention (PCI) volumes are growing faster in Canada relative to other developed markets, such as the United States and Europe. This growth will be largely driven by the increase in penetration of PCI procedures relative to coronary artery bypass graft surgeries and increasing use of intravascular imaging and pressure devices. However, declining prices will result in relatively flat market growth overall.

Other key findings from Decision Resources Group's coverage of the Canadian IC device market:

  • Faster PCI growth compared to the U.S.: PCI volumes in Canada are also growing faster than in the U.S. because Canadian physicians have been slower to adopt intravascular imaging catheters and pressure guidewires. Although these devices help identify appropriate stenting candidates, thereby reducing unnecessary stenting procedures, use of these devices has been lower in Canada due to budget constraints.
  • Increasing emphasis on identifying stenting candidates: However, as prices of intravascular imaging catheters and pressure guidewires come down, Canadian physicians will increasingly adopt these tools. As a result, the number of stenting procedures will decline, limiting PCI volumes somewhat.
  • Declining prices: The Canadian IC device market will also be hindered by declining prices, especially for drug-eluting stents, which represent the largest portion of IC device revenues.

Comments from Decision Resources Group Analyst Sivani Paskaradevan:

  • "Price declines are largely a result of the strong presence of group purchasing organizations and long-term tenders in Canada. Price is therefore the primary determinant of purchasing in the country because hospitals are extremely cost-conscious. As a result, companies are being pressured to decrease prices significantly in order to secure purchasing contracts."
  • "A number of new technologies are poised to enter the Canadian IC device market in the coming years. For example, Abbott is anticipated to release its bioresorbable vascular scaffold technology in 2017, and C. R. Bard and Medtronic are both expected to launch drug-coated balloons in 2018. In addition to the major multinational competitors, Opsens—which is a domestic competitor—is anticipated to launch its fractional flow reserve guidewire within a year."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO 


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Announces Early Termination of HSR Act Waiting Period and Canadian Competition Act Compliance in Connection with Its Proposed Acquisition of Paladin Labs
2. Canadians Now Benefit From Radiology Quality Monitored in Real-Time
3. Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health
4. Kush Bottles Announces New Canadian Division
5. Medbox Targets Newly Emerging $1.3 Billion Canadian Medical Marijuana Market
6. Montmed to Launch DiaClin General & Diabetic Skin Care Product Line for Canadian Marketplace
7. MicroConstants China In-licenses Phase 2 Liver Cancer Drug from Canadian Pertinax Therapeutics
8. AsepticSure Distribution Agreement Opens Door To Canadian Hospital Market
9. Quebec Clinic Launches Canadian Use of Elektas Agility Beam-Shaping Innovation for Radiation Therapy of Cancer
10. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
11. Interventional Cardiology Devices Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):